aap Implantate AG (DE:AAQ1)
XETRA:AAQ1
Top Page
aap Implantate
(XETRA:AAQ1)
Select Model
Select Model
Rating:51Neutral
Price Target:
€1.50
▲(19.05% Upside)
Action:ReiteratedDate:01/14/26
The score is held back primarily by weak financial performance, driven by ongoing losses and negative operating/free cash flow, despite improved leverage and revenue growth. Technicals are relatively supportive with price above key averages and a positive MACD, but momentum indicators are stretched. Valuation is also constrained by a negative P/E that signals continuing unprofitability.
Positive Factors
Improved leverage (debt-to-equity)
A lower debt-to-equity ratio materially reduces financial risk and interest burden, improving flexibility to fund R&D and commercial expansion. Over 2–6 months, sustained low leverage supports resilience through surgical sales cycles and reduces refinancing vulnerability.
Negative Factors
Persistent negative profitability
Negative operating and reported profits show the company is not yet converting sales into sustainable earnings. Persisting margin deficits constrain reinvestment, make break-even distant, and can force pricing or cost trade-offs that weaken competitive positioning over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage (debt-to-equity)
A lower debt-to-equity ratio materially reduces financial risk and interest burden, improving flexibility to fund R&D and commercial expansion. Over 2–6 months, sustained low leverage supports resilience through surgical sales cycles and reduces refinancing vulnerability.
Read all positive factors
aap Implantate (AAQ1) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€20.31M
Dividend YieldN/A
Average Volume (3M)620.00
Price to Earnings (P/E)―
Beta (1Y)-0.43
Revenue Growth-0.59%
EPS Growth24.03%
CountryDE
Employees87
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding14,716,976
10 Day Avg. Volume259
30 Day Avg. Volume620
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.20
Price to Sales (P/S)1.03
P/FCF Ratio-8.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
aap Implantate Business Overview & Revenue Model
Company Description
aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range...
How the Company Makes Money
aap Implantate generates revenue primarily through the sale of its orthopedic and trauma-related products to hospitals and surgical centers. The company's revenue model is based on direct sales of its implantable devices, which are often sold in c...
aap Implantate Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.20M | 11.48M | 11.52M | 12.17M | 9.33M |
| Gross Profit | 10.67M | 9.74M | 10.58M | 2.32M | -2.16M |
| EBITDA | -1.19M | -3.43M | -1.57M | -520.00K | -5.40M |
| Net Income | -3.63M | -5.13M | -2.56M | -2.52M | -8.94M |
Balance Sheet | |||||
| Total Assets | 15.84M | 19.47M | 20.23M | 22.95M | 19.71M |
| Cash, Cash Equivalents and Short-Term Investments | 2.46M | 1.64M | 236.00K | 2.11M | 885.00K |
| Total Debt | 1.72M | 5.29M | 3.17M | 5.08M | 4.36M |
| Total Liabilities | 5.38M | 8.63M | 7.40M | 10.18M | 9.41M |
| Stockholders Equity | 10.46M | 10.85M | 12.83M | 12.78M | 10.29M |
Cash Flow | |||||
| Free Cash Flow | -1.45M | -3.40M | -2.38M | -2.99M | -4.09M |
| Operating Cash Flow | -1.12M | -2.99M | -1.89M | -2.47M | -3.67M |
| Investing Cash Flow | -327.00K | -397.00K | -469.00K | 155.00K | -140.00K |
| Financing Cash Flow | 2.22M | 4.42M | 475.00K | 3.53M | 1.77M |
aap Implantate Technical Analysis
Negative
1.26
Price Trends
1.44
Negative
1.43
Negative
1.54
Negative
Market Momentum
-0.02
Positive
44.28
Neutral
46.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AAQ1, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.44, and below the 200-day MA of 1.54, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.28 is Neutral, neither overbought nor oversold. The STOCH value of 46.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:AAQ1.
aap Implantate Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €892.30M | 19.58 | 20.78% | 1.11% | 9.64% | 35.18% | |
65 Neutral | €2.23B | 17.81 | 6.77% | 1.50% | 7.82% | -19.80% | |
60 Neutral | €15.25M | -39.63 | 3.75% | 3.46% | -23.48% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €20.31M | -11.74 | -24.16% | ― | -0.59% | 24.03% |
* Healthcare Sector Average
DE:AAQ1
aap Implantate
1.38
-0.27
-16.36%
DE:AFX
Carl Zeiss Meditec
24.88
-25.19
-50.31%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
14.26
-0.86
-5.71%
DE:GME
Geratherm Medical
2.80
-0.45
-13.82%
DE:MF6
MagForce AG
0.01
>-0.01
-33.33%
DE:E8X
elexxion AG
0.07
-0.08
-53.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.